Sunday , July 22 2018
Home / Resources / Case Studies / Avandia Tied To 43% Increased Heart Attack Risk In Study

Avandia Tied To 43% Increased Heart Attack Risk In Study

May 22, 2007

Analysis Reveals Avandia Linked To 43 Percent Increased Risk For Heart Attack And 64 percent greater risk of Ccardiovascular Death. Avandia, the biggest-selling diabetes drug in the world, is linked to a greater risk of heart attack and possibly death, says a new scientific analysis published online Monday.

More than 6 million people worldwide have taken the drug sold by London-based GlaxoSmithKline PLC since it came on the market eight years ago. Pooled results of dozens of studies revealed a 43 percent higher risk of heart attack and a 64 percent greater risk of cardiovascular death, according to the review published by the New England Journal of Medicine.

Experts said the overall risk was small and cautioned people not to stop taking the drug on their own but to talk to their doctors.

"There are more heart attacks, more strokes, deaths, et cetera," one of the study’s researchers, Dr. Steven Nissen, said. "It is most urgent that both the FDA and the company look at the original source data and do careful analysis."

The company downplayed the report of heart risks, saying the analysis by Dr. Nissen and statistician Kathy Wolski at the Cleveland Clinic is not definitive scientific proof. In a conference call Monday, Dr. Lawson McCartney, who leads Glaxo’s diabetes drug development, said the company is not seeing "anything like" the problems reported in the medical journal.

"We remain very confident in the safety and of course in the efficacy of Avandia as an important diabetic medicine," McCartney said.

GlaxoSmithKline earns $3 billion a year from the drug, the biggest-selling diabetes drug in the world, according to Forbes magazine.

The government will take no immediate action on a label change or other measures regarding the drug, said Dr. Robert J. Meyer of the U.S. Food and Drug Administration’s Center for Drug Evaluation and Research.

FDA officials acknowledged that Glaxo submitted information last August indicating some increased risk from the drug but that other studies were contradictory.

FDA said it has studied the same data as Dr. Nissen, but that "unpublished data" suggests "contradictory evidence about (Avandia’s) risks" — which essentially means the FDA doesn’t have enough evidence to pull the drug off the market.

However, several members of Congress expressed alarm at the report and said they would hold hearings on the safety issues.

In a strongly-worded editorial acommpanying the study, patients were warned not to quit Avandia on their own without discussing their concerns with their doctors, wrote Drs. Bruce Psaty and Curt Furberg. To the extent that the new analysis shows valid risks, the drug "represents a major failure of the drug-use and drug-approval processes in the United States," they said.

Psaty, a researcher at the University of Washington in Seattle, said the Nissen study means there’s no good reason for most patients to take Avandia.

When the drug was approved, "evidence was at best mixed" on its benefit, wrote the two doctors. Both have been frequent critics of the FDA’s failure to spot dangers in the drug approval process and its conduct in the case involving Vioxx. The popular arthritis medicine sold by Merck & Co. was taken off the market in 2004 when heart problems came to light after it had been taken by millions of people

Several experts said Avandia was another example of the FDA failing to detect a safety problem early enough.

In a study published last September, the drug rosiglitazone (Avandia) appeared to cut the risk of developing diabetes or dying by more than half. It also helped restore normal blood-sugar function in many participants. That study involved about 5,000 people with "pre-diabetes," or blood-sugar abnormalities.

But even that study’s researchers acknowledged that a small percentage of those on Avandia developed heart failure.



Study links regular exercise to a 41% reduction in ED:  All it took was about 30 minutes of walking a day. Although erectile dysfunction is not life-threatening, it can surely impair quality of life. A Harvard study linked regular exercise to a 41% reduction in the risk of erectile dysfunction — And in 2004, a randomized clinical trial reported that moderate exercise (averaging less than 28 minutes a day) can help restore sexual performance in obese, middle-aged men with erectile dysfunction.  Harvard Men’s Health May 2007